What Eton Pharmaceuticals, Inc. told the SEC could break it.

Eton's product distribution is highly concentrated in a single specialty-pharmacy channel: AnovoRx product sales represented 88.4% of net accounts receivable at December 31, 2025 (96.2% in 2024), so the loss of, or a disruption/payment default by, AnovoRx would materially impair Eton's product distribution and cash collection.

“AnovoRx product sales represented 88.4 % and 96.2 % of net accounts receivable.”

Eton funds its acquisition-driven rare-disease strategy partly with debt: it expanded its SWK credit facility to $30.0 million (bearing interest at SOFR plus 6.75%) and issued warrants to SWK, and it carries numerous contingent milestone and tiered-royalty obligations to product licensors; servicing this floating-rate debt and meeting milestone/royalty payments depends on continued product cash flow and capital-markets access, exposing it to interest-rate and refinancing risk.

“the Company's amendment to expand its existing credit facility to $ 30.0 million with SWK, the Company issued 289,736 warrants to SWK at a price of $ 5.32 per share.”

Eton's commercial and pipeline products depend on FDA approvals and manufacturing-change clearances, and its sales/marketing and educational-grant activities expose it (directly or via customers/partners) to U.S. fraud-and-abuse laws including the Anti-Kickback Statute and False Claims Act, where investigations or enforcement could bring significant penalties; U.S. cost-containment/healthcare reform and, for any ex-U.S. commercialization, national price controls and health-technology-assessment processes could delay launches and cut net prices.

“We may also be subject, directly or indirectly through our customers and partners, to various fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute, U.S. False Claims Act, and similar state laws”

Eton relies entirely on third-party contract manufacturers and has concentration risk in its supply chain, including single- or sole-source suppliers and CMOs, with certain raw materials, intermediates, components or finished products sourced from, processed in, or dependent on suppliers in the People's Republic of China or other higher-risk geographies; U.S. or foreign export controls, sanctions or restrictions on foreign CMOs could impair its ability to qualify, audit or use affected suppliers and disrupt product supply.

“We have concentration risk within our supply chain, including reliance on single- or sole‑source suppliers and contract manufacturers, and certain raw materials, intermediates, components or finished products may be sourced from, processed in, or otherwise dependent on suppliers located in the People's Republic of China or other higher‑risk geographies.”